1 Min Read
Nov 13 (Reuters) - Arbutus Biopharma Corp
* Arbutus’ LNP Licensee Alnylam receives accelerated assessment of patisiran from European Medicines Agency (EMA) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.